HS-243 NEW
| Price | $48 | $113 | $197 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-10 |
Product Details
| Product Name: HS-243 | CAS No.: 848249-10-5 |
| Purity: 98.62% | Supply Ability: 10g |
| Release date: 2025/11/10 |
Product Introduction
Bioactivity
| Name | HS-243 |
| Description | HS-243 is an inhibitor of IRAK-4 and IRAK-1 with IC50s of 20 and 24 nM. HS-243 shows anti-inflammatory and anticancer activity. |
| In vitro | HS-243 shows minimal TAK1 (transforming growth factor β-activated kinase 1) inhibition activity, with a IC50 of 0.5 μM. HS-243 (0-10 μM) inhibits cell survival by 21% for AN3-CA pancreatic cancer cells, and 13% for SKOV-3 ovarian cancer cells. HS-243 (10 μM) potently reduces the pro-inflammatory response of RA cells and macrophages and significantly reduces the secretion of 15 cytokines, including IL-8, CD14, GRO-α, MIP-1a, MIP-3a, uPAR, Osteopontin, MMP-9, MCP-1, I-TAC, TIM-3, IP-10, GDF-15, and RANTES[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 10 mg/mL (30.83 mM), Sonication is recommended. |
| Keywords | tumor necrosis factor | TNF | THP-1 | TAK1 | rheumatoid arthritis | RA-FLSs | IRAK-4 | IRAK-1 | IRAK | Interleukin-1 receptor associated kinase | interleukin | Inhibitor | inhibit | immunology | IL-1R associated kinase | HS-243 | HS243 | HS 243 | H460 | Cyclin dependent kinase | CLK4 | CDK | autoimmune disease | anti-inflammatory | AN3-CA |
| Inhibitors Related | Ribociclib | Ro-3306 | Abemaciclib | Rafoxanide | sodium lauroyl-α-hydroxyethyl sulfonate | ANTHRAQUINONE-2-CARBOXYLIC ACID | Palbociclib monohydrochloride | CASIN | Palbociclib | GW 441756 | Dinaciclib | Abemaciclib methanesulfonate |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | MAPK Inhibitor Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1520.00/25mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-08-21 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $997.00/50mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-10-27 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY